CCO Treatment Updates
Redefining the Frontiers of First-Line Antiretroviral Therapy: A Decade of Progress in Effective HAART
How Potent and Durable Can First-Line Therapy Be? |
Module 1 of 4 |
|
Program Director: Joseph J. Eron, Jr., MD
|
|
Trevor Hawkins, MD, reviews data from major clinical trials that have informed use of antiretroviral therapy in treatment-naive patients.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe the results of clinical trials evaluating the efficacy of antiretroviral therapy in treatment-naive patients
- Identify factors associated with durable efficacy of first-line antiretroviral options
- Discuss guideline recommendations on preferred and alternative first-line antiretroviral regimens
|
How Convenient Can First-Line Therapy Be? |
Module 2 of 4 |
|
Program Director: Joseph J. Eron, Jr., MD
- Kimberly Y. Smith, MD, MPH
|
|
|
Kimberly Y. Smith, MD, MPH, reviews the importance of regimen simplicity and convenience in first-line antiretroviral therapy.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Identify barriers to adherence to antiretroviral therapy
- Describe recommended strategies to improve adherence to antiretroviral therapy
- Discuss clinical trials evaluating options for first-line antiretroviral therapy
|
How Well Tolerated Can First-Line Therapy Be? |
Module 3 of 4 |
|
Program Director: Joseph J. Eron, Jr., MD
|
|
William G. Powderly, MD, provides an extensive review of toxicities associated with antiretroviral therapy and considers how tolerability informs choice of first-line regimens.
Learning Objectives
Upon completion of this activity, participants should be able to:
- List risk factors for acute antiretroviral toxicity, including genetic correlates
- Describe long-term complications of antiretroviral therapy
- Explain treatment strategies for management of antiretroviral toxicity
|
How May First-Line Therapy Continue to Evolve? |
Module 4 of 4 |
|
Program Director: Joseph J. Eron, Jr., MD
|
|
Joseph J. Eron, Jr., MD, discusses factors influencing timing of initiation of first-line therapy and forecasts future directions in initial therapy.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Identify clinical scenarios in which initiation of antiretroviral therapy is recommended
- Discuss arguments in favor of earlier vs later initiation of antiretroviral therapy
- Describe the results of clinical trials evaluating novel antiretroviral agents in first-line antiretroviral therapy
|
CCO Slidesets
How Potent and Durable Can First-Line Therapy Be?
 |
|
Slideset by Trevor Hawkins, MD, corresponding to module above.
Format: Microsoft PowerPoint (.ppt) |
File size: 1.14 MB
|
How Convenient Can First-Line Therapy Be?
 |
|
Slideset by Kimberly Y. Smith, MD, MPH, corresponding to module above.
Format: UNKNOWN |
File size: 4.98 MB
|
How Well Tolerated Can First-Line Therapy Be?
 |
|
Slideset by William G. Powderly, MD, corresponding to module above.
Format: Microsoft PowerPoint (.ppt) |
File size: 994 KB
|
How May First-Line Therapy Continue to Evolve?
 |
|
Slideset by Joseph J. Eron, Jr., MD, corresponding to module above.
Format: Microsoft PowerPoint (.ppt) |
File size: 1.40 MB
|
Disclaimer: The materials published on the Clinical Care Options
Web site reflect the views of the reviewers or authors of the
CCO
material, not those of Clinical Care Options, LLC, the CME provider,
or the companies providing educational grants. The materials may
discuss uses and dosages for therapeutic products that have not been
approved by the United States Food and Drug Administration. A qualified
healthcare professional should be consulted before using any therapeutic
product discussed. Readers should verify all information and data before
treating patients or using any therapies described in these materials.
|
Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.
Contact Info
Supported by an unrestricted educational grant from
Educational grants support only the CME-certified components of this program.
|